NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Navin Fluorine International Ltd.’s Ebitda/profit after tax grew 13%/42% YoY in Q4 FY24, higher than our estimates. The beat was driven by a strong performance in the specialty chemicals business, which was well supported by growth in the high-performance product segment. Gross margin was 50%, while Ebitda margin dipped 10.7pp YoY to 18.3%.
The specialty chemicals business posted strong revenue growth of 26% YoY, led by higher utilisation at the Surat plant and the addition of new molecules (one in Dahej and two in Surat). Management highlighted that it is much better placed with long term take-or-pay contracts with its customers. Currently, 80% of the revenue is contributed by the agrochemicals sector. Navin Fluorine anticipates launching three-four new molecules every year in this space.
The HPP business grew 3% YoY, led by R22 and R32 plants that are running at full capacity, with positive pricing trends being seen in the domestic market for R32. Management seeks to double the R32 capacity that is expected to be commissioned by Feb-25. The HFO plant has stabilized, and the volumes are higher than the previous three quarters. Management also highlighted that the Ref Gas market is showing signs of recovery.
Navin Molecular continued its weak performance with a revenue decline of 76% YoY in Q4, and some deferral in molecules while some molecules did not get timely approvals by the customers. Despite this, management mentioned that it has a strong late-stage pipeline/commercial opportunities in the business. The BoD has also approved a capex of Rs 2.9 billion for its cGMP-4 plant with Phase-1 outlay of Rs 1.6 billion that is likely to be commissioned by end-CY25.
We have not made any material changes to our estimates as of now. Subsequently, we expect a revenue/Ebitda/profit after tax compound annual growth rate of 23%/34%/39% over FY24-26. The stock is trading at 38 times FY26E EPS of Rs 89 and 25 times FY26E EV/Ebitda.
We value the company at 35 times FY26E EPS to arrive at our target price of Rs 3,110. We reiterate our Neutral rating on the stock.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

JK Cement's Strong Show To Continue, Says HDFC Securities Maintaining 'Add' — Check New Target Price


Why Is Apollo Hospitals Stock Poised For Re-Rating? Read PL Capital Report


'Buy' Samvardhana Motherson To Get An Upside Of 20% Says Yes Securities, Sees Strong Growth Across Verticals


'Buy' ACME Solar Shares Maintains Motilal Oswal Post Strong Q1 Results — Check Target Price
